Alexander Spira, MD, PhD, FACP

No bio available.

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Bristol-Myers Squibb
    Date added: 
    08/16/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Loxo
    Date added: 
    08/16/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Arch Therapeutics
    Date added: 
    08/16/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Gritstone
    Date added: 
    08/16/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Plexxikon
    Date added: 
    08/16/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Amgen
    Date added: 
    08/16/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Loxo
    Date added: 
    08/16/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Daiichi Sankyo
    Date added: 
    08/16/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    ADCT
    Date added: 
    08/16/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Janssen Oncology
    Date added: 
    08/16/2023

Pages

Return to 2023 Annual Symposium For Evolving Therapies and Drug Development in Oncology: Targeted therapy, immunotherapy and beyond